Chimeric Polypeptides for S. aureus Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing vaccines against Staphylococcus aureus are time-consuming, labor-intensive, and often ineffective due to limitations in culturing microorganisms and identifying protective antigens.
Innovation Solution
The development of novel recombinant chimeric polypeptides and polynucleotides derived from Staphylococcus aureus, which can be used as immunogens to induce protective immunity against S. aureus infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional empirical approach is used for subunit vaccine development, then vaccine development can be pursued, but the process is time-consuming and labor-intensive
Solution Approach 1:
The patent applies preliminary action by using computational methods and bioinformatics tools to predict and identify protective antigens before actual vaccine development. The system pre-processes genomic data, predicts antigenic properties, and screens for candidate proteins in advance, thereby avoiding time-consuming empirical testing of numerous proteins and significantly accelerating the vaccine development process.
2Productivity
If traditional empirical approach is used for subunit vaccine development, then vaccine development can be pursued, but the process is labor-intensive and expensive
Solution Approach 1:
The patent applies copying by using computational models and digital representations of proteins and genomic data instead of physically handling and testing large quantities of actual proteins. The system creates virtual models of bacterial proteins, predicts their immunogenicity through computer algorithms, and screens candidates in silico, thereby eliminating the need to produce and test extensive protein libraries and significantly reducing material requirements and costs.
3Measurement precision
If traditional empirical approach is used, then antigen identification can be performed, but protective antigens are difficult to identify among abundant proteins
Solution Approach 1:
The patent applies local quality by focusing computational analysis on specific regions and properties of proteins that are likely to be protective. The system evaluates local characteristics such as surface accessibility, conservation across strains, and specific structural motifs that are indicative of protective antigens, rather than uniformly analyzing all proteins. This targeted approach enables precise identification of protective antigens by examining their local functional properties and distinguishing them from abundant non-protective proteins.
Data Source
AI summary
Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.